We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

The primary endpoint is overall survival (OS) in participants with PD-L1 TPS =50%. Secondary endpoints include OS in participants with PD-L1 TPS =1% and TPS 1-49%, progression-free survival (PFS), ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

We recently compiled a list of the 10 Chinese Penny Stocks to Buy According to Analysts. In this article, we are going to ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

US biotech Checkpoint Therapeutics saw its shares jump more than 16% to $4.27 in after-hours trading on Friday, on the news ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...